Stealth resubmits rare disease drug to FDA
The biotech, which cut jobs following the rejection in May of its Barth syndrome therapy, claimed it has addressed the agency’s concerns and now sees potential for a speedy review.
Previous Post
Four Proven Ways to Rejuvenate Your Face
Next Post
Managing Mood Swings: What’s Normal and What Isn’t
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago